Product Highlight - SPIKEVAX JN.1

• Spikevax^® JN.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older¹

• Tolerable safety profile: Most common side effects include injection site pain, fatigue, headache, myalgia and arthralgia.¹

• Simple administration: Pre-filled syringe for intramuscular injection¹

Reference: 1. Spikevax^® JN.1 dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine 50 micrograms/dose 0.5 mL Prescribing Information. September 2024